Biosimilars, also known as follow-on biologics, continued to capture greater market share and foment stronger competition with reference or brand name drugs in 2021. Increasing the number of biosimilars in the market and amplifying uptake by payers, family medical practices and pharmacies could be a gamechanger for patients and a healthcare system trying to reduce the cost of life-changing medicines.
At ACC we deal with manufacturing companies from many different industries. We have run into some of the same issues affecting our customers, no matter the industry, time and time again. We have compiled our list of the #top5 issues affecting manufacturing this year.
Azita Adli is a passionate, innovative, and quality-minded professional with 10+ years of experience within the pharmaceutical industry. Azita has held roles within production, investigation, quality systems, and central quality throughout her career, supporting sites within GlaxoSmithKline’s (GSK’s) Pharmaceutical Supply Chain.